📇 Rhumatologue · BOURGOIN JALLIEU · (38) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
7 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
120.1 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
11
11 articles ont été cités au moins 11fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
552
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
22
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
11
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Antineoplastic chemotherapy and immunosuppression in liver transplant recipients: Squaring the circle?
2023ArticleClinical Transplantation
Tacrolimus exposure after liver transplantation for alcohol-related liver disease: Impact on complications
2019ArticleTransplant Immunology
Immunosuppressive regimen and risk for de novo malignancies after liver transplantation for alcoholic liver disease
2018ArticleClinics and Research in Hepatology and Gastroenterology
Subsequent nonmelanoma skin cancers and impact of immunosuppression in liver transplant recipients
2018ArticleJournal of The American Academy of Dermatology
Prognostic factors in patients with refractory ascites treated by transjugular intrahepatic porto-systemic shunt: From the liver to the kidney
2014ArticleDigestive and Liver Disease
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GASTRO NORD ISERE
SELARL GASTRO NORD ISERE 37 AVENUE DU MEDIPOLE, 38300 BOURGOIN JALLIEU
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2014
Nonalcoholic fatty liver disease (NAFLD) is a potential long-term complication after liver transplantation (LT) and can occur as recurrent disease in patients undergoing transplantation for NAFLD or as de novo NAFLD in others. The aim of this study was to compare these 2 different entities. From a cohort of adult patients undergoing transplantation between 2000 and 2010, we selected all patients with a diagnosis of NAFLD made during liver biopsy examinations during post-LT follow-up; clinical, biological, and histological features of patients with recurrent NAFLD and patients with de novo NAFLD were compared. The diagnosis of post-LT NAFLD was made for 91 patients during the study period: 11 cases were classified as recurrent NAFLD, and 80 cases were classified as de novo NAFLD. The groups were not statistically different with respect to the sex ratio, age, prevalence of hypercholesterolemia, prevalence of obesity, or prevalence of hypertension. The prevalence of diabetes mellitus was higher in patients with recurrent NAFLD (100% versus 37.5%, p < 0.01). At 5 years, severe fibrosis (stage 3 or 4) and steatohepatitis were more frequent in patients with recurrent NAFLD versus patients with de novo NAFLD [71.4% versus 12.5% (P < 0.01) and 71.4% versus 17.2% (P < 0.01), respectively]. NAFLD was already present in 67% of the patients with de novo NAFLD and in 100% of the patients with recurrent NAFLD after 1 year. According to successive liver biopsies, steatosis disappeared in 18 patients (22.5%) with de novo NAFLD and in none of the patients with recurrent NAFLD. In conclusion, our results strongly suggest that recurrent NAFLD and de novo NAFLD after LT are different entities; recurrent NAFLD appears to be a more severe and irreversible disease with an earlier onset. Liver Transpl 20:1064-1071, 2014. © 2014 AASLD.
European radiology · 2013
Clinical transplantation · 2014
AbstractDe novo malignancies are a main cause for late death after liver transplantation (LT). Everolimus (ERL) is an immunosuppressive agent with antitumoral properties. The aim of the present retrospective study was to identify prognostic factors, including conversion to ERL, for patients presenting non‐cutaneous de novo solid organ malignancy after LT for alcoholic cirrhosis. The study population consisted of 83 patients (presenting 100 tumors, including 75% of upper aerodigestive tract cancers), among the 398 patients who underwent LT for alcoholic cirrhosis in our center. After diagnosis, ERL was introduced in 38 patients and calcineurin‐inhibitor was discontinued in 64.1% of them. Tumor stage was a significant prognostic factor with a one‐yr survival at 82.6% for early stages, 63.4% for intermediate stages (N+) and 27.4% for disseminated diseases (p < 0.001). Associated relative risk factor was 2.202 (95% CI 1.044–4.644) for intermediate stages and 5.743 (95% CI 2.436–13.541) for metastatic stages. One‐ and five‐yr survival was 77.4% and 35.2% in ERL group vs. 47.2% and 19.4% in the non‐ERL group, respectively (p = 0.003). The relative risk factor for ERL was 0.447 (95%CI 0.257–0.778). Our results strongly suggest that conversion to ERL improves the prognosis of de novo malignancies after LT for alcoholic cirrhosis. Prospective studies are needed to confirm this benefit.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Clinical transplantation · 2024 · Journal Article
Erard D, Steiner A, Boillot O, Thimonier E, et al.
Transplant immunology · 2019 · Journal Article
Bardou FN, Guillaud O, Erard-Poinsot D, Chambon-Augoyard C, et al.
Clinics and research in hepatology and gastroenterology · 2018 · Journal Article
Dumortier J, Maucort-Boulch D, Poinsot D, Thimonier E, et al.
Clinical transplantation · 2014 · Clinical Trial
Thimonier E, Guillaud O, Walter T, Decullier E, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2014 · Journal Article
Hamel B, Guillaud O, Roman S, Vallin M, et al.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2014 · Comparative Study
Vallin M, Guillaud O, Boillot O, Hervieu V, et al.
European radiology · 2013 · Journal Article
Guibal A, Boularan C, Bruce M, Vallin M, et al.